secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001193125-21-315472
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault
---------------------------------------------------------------------------

- Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.
- Compensation: $450k base salary, bonus up to 45% of base, and option for 200k shares vesting over 4 years.
- Giacobello was CFO of GW Pharma (acquired by Jazz for $7.2B); led EPIDIOLEX launch with $296M first-year sales.
- Company faces PDUFA date Nov 26, 2021 for lead drug FYARRO in malignant PEComa.
- Lance Thibault, interim CFO since July 2021, will leave the role on the effective date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/d173598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-315472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer